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 Ethylenediamine tetraacetic acid (EDTA) is used in various medical applications. The aim of this 
study is to investigate the antitumor efficacy of EDTA alone or with cisplatin (Cis). Fifty male albino 
mice were used to assess the median lethal dose (LD
50
) of EDTA via intraperitoneal (i.p) injection. 
To determine the antitumor activity, fifty female albino mice were divided into five groups as the 
following; Group 1 (Gp1) was negative control; (Gp2-5) inoculated i.p with 2×106 Ehrlich Ascites 
Carcinoma (EAC) cells/mouse. After one day, Gp3, Gp4 and Gp5 injected with Cis (2 mg/kg), EDTA 
(25 mg/kg) and Cis (2 mg/kg)/EDTA (25 mg/kg) for six days, respectively. At day 14, all groups 
were sacrificed to assess the tumor profile, liver enzymes (alanine transaminases and aspartate 
transaminases), kidney function (urea and creatinine) and electrolytes (Na+, K+ and Ca2+). The results 
showed that the i.p LD
50
 of EDTA was 250 mg/kg. Treatment with EDTA alone did not show any 
antitumor activity and did not interfere with the antitumor efficacy of Cis. Biochemical findings 
revealed that EDTA had mild toxicity on liver and kidneys functions. In summary, EDTA had no 
antitumor effect and did not alter the Cis efficacy.
Keywords: Cisplatin. Ethylenediamine tetraacetic acid (EDTA)/Antitumor efficacy. Ehrlich Ascites 
Carcinoma.
INTRODUCTION
Ethylenediaminetetraacetic acid (EDTA) is known 
as a metal chelating agent. It is used in clinical setting 
to treat heavy metal intoxication such as lead, cadmium 
poisoning (Thomas et al., 2005; Myint et al., 2009). In 
addition, EDTA was used in combinations with other 
therapeutic agents to improve skin protection from 
sun radiation (Juzeniene et al., 2007). EDTA might 
prevent iron to form complex with doxorubicin, which 
could prevent damaging induced by reactive oxygen 
species (Hasinoff, 2006). It is commonly used also to 
treat cardiovascular diseases (Chappell, Janson, 1996). 
Furthermore, EDTA could be important as an adjuvant 
for increasing the intratumoral efficacy of cisplatin (Cis) 
treatment (Duvillard et al., 2004; Pajak, Orzechowski, 
2007). It may also inhibit the bleomycin nucleases 
activity, which in turn induces cancer cell apoptosis 
(Aouida et al., 2007). Recently, it has been reported that 
treatment of different cancer lines with EDTA in vitro 
showed antitumor activity (Feril et al., 2017). 
In regard to the toxicity and the possible 
carcinogenicity of EDTA, several studies reported 
that the treatment with EDTA (750 mg/kg/day) was 
considered as the lowest dose that caused a toxic effect 
in animals but not carcinogenic agent (Kimmel, 1977). 
Cisplatin (Cis) is a well-known as a potent 
chemotherapeutic agent to combat different types of 
cancers, including breast, prostate and bladder (Cepeda 
et al., 2007; El-Naggar, 2011). The mode of action of Cis 
is to cross-link with the DNA purine bases, which in 
turn interfere with DNA repair. DNA damage followed 
by activation of p53 resulting in cancer cells apoptosis 
(Damia et al., 2001). Combination therapies of Cis with 
other drugs have been highly considered to overcome 
drug-resistance, synergistic effects and reduce toxicities 
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(Dasari, Tchounwou, 2014). For instance, it has been 
reported that ibuprofen administration with Cis 
accelerates the apoptosis (Endo et al., 2014). This study 
aimed to address the antitumor efficacy of EDTA on 
EAC-bearing mice and its impact on Cis treatment. The 
results indicated that EDTA treatment did not show any 
antitumor activity; however, treatment of mice with Cis 
and EDTA did not interfere with the mode of action of 
Cis as anticancer agent but exhibited mild toxicity on 
kidneys and liver tissues.
MATERIAL AND METHODS
Chemicals
Cisplatin (cis-diamminedichloroplatinum II) was 
purchased from the local pharmacy. It is manufactured 
by EIMC united pharmaceuticals, Egypt. Each vial 
contains 50 mg/50 mL. At the time of treatment, Cis was 
diluted by 0.9% normal saline and adjusted to 2 mg/kg 
b.wt in 200 µL. EDTA was purchased from commercial 
company (Al-Gomhorea, Tanta, Egypt). EDTA was 
prepared as 25 mg/kg in 200 µL of 0.9% sterilized saline.
Mice
Female Swiss albino mice weighting 20 ± 2 g 
were obtained from National Research Center (NRC, 
Cairo, Egypt). Animals were housed (5/cage), in 12 
H/12 H dark/light cycle under laboratory condition of 
temperature and humidity. Mice were kept for a week 
before starting the experiment for adaptation and then 
handled according to the ethical guidelines approved by 
the animal care and use committee, Faculty of Science, 
Tanta University (ACUC-SCI-TU), Egypt. 
Determination the median lethal dose (LD50) 
of EDTA by intraperitoneal (i.p) injection
To determine the lethal dose (LD50) that kills 
50% of mice after i.p. injection of EDTA, fifty mice 
were divided into two main groups (n=25) to repeat 
the experiment twice. Each group further divided into 
5 subgroups of 5 mice per each. Then, these subgroups 
were injected i.p by different concentrations of EDTA 
(0.1 g/kg to 0.5 g/kg). Mice were noticed for 24 h to 
assess the acute toxicity of EDTA. LD50 value was 
calculated using the arithmetic method of Karber as 
modified by Aliu and Nwude (1982) according to the 
following equation, the theoretical LD50 = LDy - sum 
(Dd x Md)/N. 
Ehrlich Ascites Carcinoma (EAC) 
cells and tumor inoculation
Ehrlich ascites carcinoma (EAC) bearing mice 
were purchased from the National Institute of Cancer 
(Cairo, Egypt). EAC cells were collected from the tumor 
bearing mice, and had diluted in sterile 0.9% saline. The 
viable and dead EAC cells were counted using trypan 
blue method and the number was adjusted at 2×106 cells/
mouse for inoculation. Total viable cells were calculated 
as following: Mean number of unstained cells × dilution 
× 104/mL.
Experimental design
Fifty female Swiss albino mice were divided into 
five groups (n = 10). Group 1 (Gp1) served as a control 
and injected intraperitonially (i.p) with 200 µL of 0.9% 
saline. Gp2 (EAC-bearing mice), mice inoculated i.p 
with 200 µL of 2 ×106 cells/mouse on day 0. Gp3, Gp4 
and Gp5 were inoculated with the same number of EAC-
cells as in Gp2. These groups were treated i.p either with 
Cis (2 mg/kg) or EDTA (25 mg/kg) or with Cis (2 mg/kg)/ 
EDTA (25 mg/kg). The treatment with saline, Cis, 
EDTA or EDTA/Cis started from day 1 until day 6. On 
day 14, all groups were sacrificed to assess the tumor 
volume, count and live/dead cells. 
Determination the percentage of the 
total body weight changes 
All mice in the five groups under the study were 
weighted at day 0, and then by day 14. The percentage of 
the change in the total body weight (T.B.W) was assessed 
as follow: (T.B.W at day 14 – T.B.W at day 0/T.B.W at 
day 0) × 100. 
Biochemical and electrolytes assays
Serum alanine transaminases (ALT), aspartate 
transaminases (AST), urea, creatinine, and total 
lipids were assayed by the colorimetric method using 
kit (Diamond-Diagnostics, Egypt). Additionally, 
electrolytes including calcium (Ca2+), sodium 
(Na+) and potassium (k+) were assayed in serum by 
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the colorimetric method using kit (Diamond- 
Diagnostics, Egypt).
Statistical analysis
One–way analysis of variance (ANOVA) was used 
to assess the significant differences among treatment 
groups. Dunnet test was used to compare all groups 
against the control group to show the significant effect 
of treatment. The criterion for statistical significance 
was set at p <0.05 or p <0.01. All data are presented as 
mean ± SD.
RESULTS
LD50 of EDTA after intraperitoneal 
(i.p) injection in mice
According to the obtained results of the two 
separate experiments, the mortality rate of mice was 
calculated from each dose of EDTA. The results showed 
that the calculated LD50 of EDTA was 250 mg/kg after 
injection of mice i.p. as shown in Figure 1.
Treatment with Cis decrease the 
total body weight of mice
As shown in figure 2A, after 14-day of EAC-
cells inoculation, the T.B.W of mice in all groups was 
determined and the percentages of the change in the 
weight were assessed. The results showed that groups 
of mice, which inoculated with EAC cells alone (Gp2) 
or inoculated with EAC cells and treated with EDTA 
(Gp3) showed an increase in the percentage of T.B.W. 
Groups of mice which inoculated with EAC-cells and 
treated with Cis (Gp3) or mice inoculated with tumor 
cells and then treated with a combination of Cis/EDTA 
(Gp5) had no significant changes in their body weight 
when compared to Gp2.
FIGURE 1- The median lethal dose (LD50) of EDTA injected intraperitoneal (i.p.) in albino mice. 
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FIGURE 2- EDTA treatment did not show antitumor activity. A) The percentages of the change in the total body weigh in all 
groups, B) The tumor volumes. Co-treatment therapy with Cis/EDTA did not alter the efficacy of Cis antitumor. C) The total 
count of EAC cells, D) The viability of EAC cells represented by the live and dead tumor cells. 
Treatment with EDTA alone did not 
show antitumor effect in vivo
Furthermore, to assess the antitumor effect of 
EDTA on EAC-bearing mice, the results showed that 
the treatment with EDTA alone for six consecutive 
days (Gp3) did not revealed any antitumor effect when 
compared to Gp2. As shown in figure 2B treatment with 
Cis/EDTA treatment at the same time (Gp5) did not alter 
the efficacy of the Cis treatment when compared to Gp2. 
As shown in figure 2C, D and figure 3, the treatment 
with EDTA alone did not show any significant change in 
the tumor volume or the tumor counts when compared 
to the group of mice, which inoculated with EAC cells 
alone. Interestingly, the treatment with Cis/EDTA (Gp5) 
showed similar pattern in regard to the tumor cell count 
as in the group of mice which inoculated with EAC and 
treated with Cis alone (Gp3).
Treatment with Cis/EDTA substantially 
increased ALT, AST and total lipids levels
The results revealed that the levels of alanine 
transaminases (ALT) and aspartate transaminases 
(AST) were increased in groups Gp2 and Gp3. In 
addition, due to the combinatorial treatment of EDTA 
with Cis, a significant increase the serum ALT and 
AST levels when compared to Gp2 as showed in 
table I. Total lipids level in Cis-treated group or in 
group of mice which treated with EDTA alone were 
significantly increased when compared to Gp2. 
Combinatorial treatment of EDTA with Cis were 
significantly increased the level of total lipids in serum 
as compared with Gp2. (Table I). 
Antitumor efficacy of EDTA co-treatment with cisplatin in tumor-bearing mice
Braz. J. Pharm. Sci. 2020;56: e18536 Page 5/8
EAC-alone EAC/Cis. EAC/Cis/EDTA 
FIGURE 3- Photomicrographs showed the tumor volumes of EAC-bearing mice (left side), EAC-bearing mice treated with Cis 
(2 mg/kg) (middle) and EAC-bearing mice treated with Cis (2 mg/kg)/ EDTA (25 mg/kg) (right side).














Control 19.5 ± 1.5a 84.8 ± 2.9a 145 ± 3.5a 18.19 ± 0.59a 0.35 ± 0.03a
EAC alone 23.9 ± 1.0b 119.3 ± 2.5b 295 ± 2.5b 25.72 ± 0.75b 0.58 ± 0.014b
EAC/Cis 33.4 ± 2.21c 154.0 ± 1.7c 437 ± 2.9c 44.01 ± 0.84c 0.87 ± 0.04c
EAC/EDTA 42.2 ± 1.6d 177.5 ± 1.5d 762 ± 3.1d 79.62 ± 0.61d 1.30 ± 0.02d
EAC/Cis/EDTA 36.9 ± 2.5c 162.1 ± 2.0e 413 ± 3.9e 59.62 ± 0.94e ± 0.06c
*Means that don’t share a letter are significantly different
Treatment with Cis/EDTA increased 
urea and creatinine levels
Urea and creatinine levels were significantly 
increase in Cis-treated group and EDTA treated group 
when compared with Gp2. Co-treatment of EDTA with 
Cis showed a significant increases the level of urea and 
creatinine as compared with Gp2. (Table I).
Treatment with Cis/EDTA altered some minerals level
As shown in Table II, the levels of total calcium in 
EDTA-treated group were significantly decreased when 
compared with Gp2, Gp3 and Gp5. Sodium level in Cis/
EDTA treated group were increased when compared 
to Gp2, Gp3 and Gp4. The results also showed that 
potassium level did not reveal any significant changes in 
all-treated groups when compared with Gp2. 
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TABLE II - Serum electrolytes, calcium (Ca2+), sodium (Na+) and potassium (k+) concentrations in the different groups
Groups*
Electrolyte levels
Calcium (mmol/L) Sodium (mmol/L) Potassium (g/dL)
Control 6.31 ± 0.42a 150.23 ± 1.22a 4.8 ± 0.32a,b
EAC alone 7.13 ± 0.91a 148.26 ± 2.53a 4.1 ± 0.58b
EAC/Cis 6.51 ± 1.45a 138.96 ± 3.07b 5.2 ± 0.23a
EAC/EDTA 5.14 ± 2.21a 136.01 ± 1.75b 4.6 ± 0.18b
EAC/Cis/EDTA 6.86 ± 1.52a 158.13 ± 3.07c 5.8 ± 0.71a
* Means that don’t share a letter are significantly different
Furthermore, the study was extended to address 
the impact of the treatment with EDTA in combination 
with Cis against EAC-bearing mice. We thought that the 
treatment with EDTA and Cis at the same time could 
decrease Cis activity as anticancer agent. Our thought 
because that due to the possible chelation between 
EDTA and Cis. In contrast of our hypothesis, the results 
showed that there was no any significant impact of 
EDTA on the efficacy of Cis. One of our explanations 
for this unexpected result is that EDTA was able to 
remove calcium from the cell membranes, which in turn 
facilitate the entrance of Cis into the tumor cells. Our 
explanation in accordance with a previous finding, which 
reported that EDTA might increase the permeability of 
the intestinal epithelium by increasing the size of the 
membrane pores or by widening the spaces between 
the epithelial cells through the removal of calcium ions 
(LaDu, Mandel, Way, 1971). Due to the narrow window 
to determine the exact action of EDTA on the high dose 
of Cis. Further study is going to explore the direct effect 
of EDTA on the efficacy of the low dose of Cis after 
inoculation of EAC cells directly or after establishing 
EAC in mice model.
Treatment of EAC-bearing mice with EDTA for 6 
days increased the percentage of the body weight more 
or less similar to those mice inoculated with EAC-cells 
alone; this finding indicated that the treatment with 
EDTA alone has no antitumor effect. Furthermore, 
treatment with EDTA alone showed also a similar 
DISCUSSION
Cisplatin (Cis) is well known as a reference drug 
that act by binding DNA to form Cis–DNA adducts 
(Cepeda et al., 2007; Dasari, Tchounwou, 2014). On 
the other hand, EDTA is a metal chelating agent which 
able to combine with several metals so that it is used to 
remove heavy metals such as cadmium and lead from the 
body (Myint et al., 2009). EDTA is used as a potential 
therapeutic agent for vascular disease treatment (Ferrero, 
2016). Furthermore, in clinical setting of ophthalmology 
EDTA has been utilized to treat band-shaped keratopathy 
(Kobayashi et al., 2015). In addition, Ca-EDTA chelation 
removes cadmium (Cd) intoxication (Gil et al., 2011). In 
this study, our aim was to address the direct antitumor 
effect of EDTA on EAC-tumor bearing mice and to 
address it’s impact EDTA alone on the efficacy of the Cis 
treatment. Our data showed that the treatment with EDTA 
alone (25 mg/kg) for 6 consecutive days did not show any 
antitumor activity against EAC-bearing mice. This study 
was the first trial to explore the direct impact of EDTA 
on tumor bearing mice. A previous study showed that the 
intratumoral injection with EDTA increased the antitumor 
effect of Cis (Hasinoff, 2006). In addition, it has been 
reported that EDTA might prevent iron to form complex 
with doxorubicin, which could prevent reactive oxygen 
species damaging (Duvillard et al., 2004). A recent in 
vitro study showed that EDTA revealed antitumor activity 
against several tumor cell lines (Feril et al., 2017).
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pattern in regard to the tumor volume, counts of live and 
dead cells. These finding indicated that the treatment 
with EDTA alone has no antitumor effect.
The results revealed that inoculation with EAC 
for 14 days increased the levels of ALT, AST, urea and 
creatinine. Furthermore, the treatment with Cis alone or 
EDTA alone or their combination between EDTA and Cis 
increased the level of these parameters when compared 
to EAC-bearing mice alone. Acute exposure of EDTA 
may cause kidney injury, gastrointestinal upset, transient 
bone marrow depression; muscle cramps (Bingham, 
Cohrssen, Powell, 2001). Interestingly, the treatment of 
EAC-bearing mice with EDTA alone showed decrease 
in the level of calcium (Ca++). In agreement with our 
data, administration of EDTA decreased the coagulation 
factor activity resulted in a decrease in serum calcium 
levels causing profound hypocalcemia (Arla, Edward, 
2008). Khalil et al. (2008) showed that treatment 
with EDTA altered antioxidant enzymes activity and 
biochemical parameters in the serum.
Consistent with our findings several studies 
reported that the treatment with EDTA (750 mg/kg/day) 
was reported as the lowest dose that caused a toxic effect 
but not carcinogenic agent in animals (Kimmel, 1977). 
In conclusion, the data collectively showed that there is 
no anticancer activity of EDTA against EAC-bearing 
mice and did not alter the efficacy of Cis as anticancer 
agent.
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